Filtered By:
Drug: Celebrex

This page shows you your search results in order of relevance. This is page number 2.

Order by Relevance | Date

Total 37 results found since Jan 2013.

Nonsteroidal Anti-Inflammatory Drugs and Cardiovascular Outcomes in Women: Results From the Women's Health Initiative Original Articles
Conclusions— Regular use of selective cox-2 inhibitors and nonselective NSAIDs with cox-2>cox-1 inhibition showed a modestly increased hazard for cardiovascular events. Nonselective agents with cox-1>cox-2 inhibition were not associated with increased cardiovascular risk. Clinical Trial Registration— URL: www.clinicaltrials.gov. Unique identifier: NCT00000611.
Source: Circulation: Cardiovascular Quality and Outcomes - July 15, 2014 Category: Cardiology Authors: Bavry, A. A., Thomas, F., Allison, M., Johnson, K. C., Howard, B. V., Hlatky, M., Manson, J. E., Limacher, M. C. Tags: Risk Factors Original Articles Source Type: research

Certain Painkillers Tied to Raised Risk of Death After Stroke
Celebrex and other COX-2 inhibitors should be prescribed with care, experts say
Source: WebMD Health - November 5, 2014 Category: Consumer Health News Source Type: news

A Cyclooxygenase-2 Inhibitor Reduces Vascular Wall Thickness and Ameliorates Cognitive Impairment in a Cerebral Small Vessel Diseases Rat Model.
Abstract Cerebral small vessel disease (CSVD) is a group of diseases that originate from changes in cerebral small vessels and that cause many conditions, such as cognitive impairment. However, there is no effective therapy for these diseases. Recent studies have suggested that inflammation is associated with this disease. Cyclooxygenase-2 (cox-2) is an inflammatory mediator; however, whether a cox-2 inhibitor could protect against the CSVD progression remains unknown. In the present study, stroke-prone spontaneously hypertensive rats (SHRsp) were used as a model of CSVD, and Sprague Dawley (SD) rats served as the...
Source: Current Alzheimer Research - July 9, 2015 Category: Neurology Authors: Tang J, Xiao W, Li Q, Deng Q, Chu X, Chen Y, Pan D, Fu J Tags: Curr Alzheimer Res Source Type: research

FDA Strengthens Warnings on Class of Painkillers
The FDA strengthened its safety warnings about heart-attack and stroke risks linked to a class of common pain relievers that includes medicines such as Celebrex, Advil, Motrin IB and Aleve.
Source: WSJ.com: Health - July 10, 2015 Category: Pharmaceuticals Tags: PAID Source Type: news

Experts Urge Sparing Use of Nonaspirin Painkillers
The Food and Drug Administration said it would ask drug manufacturers to change the labels to reflect evidence that nonaspirin, nonsteroidal anti-inflammatory drugs increased the risk of heart attacks and strokes.
Source: NYT Health - July 14, 2015 Category: Consumer Health News Authors: SABRINA TAVERNISE Tags: Pain-Relieving Drugs Heart Aleve (Drug) Celebrex (Drug) Drugs (Pharmaceuticals) Motrin IB Food and Drug Administration Labeling and Labels (Product) Stroke Ibuprofen (Drug) Source Type: news

Gout: Sleep apnea may raise your risk
Gout is the most common type of inflammatory arthritis and affects more than 8 million adults. Men are at a higher risk than women. And according to a new study, your risk for gout also climbs if you suffer from sleep apnea, a condition where your breathing repeatedly pauses while you sleep. What exactly is gout? Gout is triggered by the crystallization of uric acid within the joints. It happens like this: Your body produces uric acid from breaking down purines, a natural waste product of living cells. Normally, uric acid is dissolved in your blood and passes through your kidneys into your urine. However, sometimes your bo...
Source: New Harvard Health Information - November 17, 2015 Category: Consumer Health News Authors: Matthew Solan Tags: Arthritis Health Sleep gout sleep apnea Source Type: news

Role of Cyclooxygenase-2 in Relation to Nitric Oxide and Endothelin-1 on Pathogenesis of Cerebral Vasospasm After Subarachnoid Hemorrhage in Rabbit
Abstract Endothelial dysfunctions that include decreased nitric oxide (NO) bioactivity and increased endothelin-1 (ET-1) bioactivity have been considered to be involved in the pathogenesis of cerebral vasospasm (CVS) after aneurysmal subarachnoid hemorrhage (SAH). Recent cardiovascular studies have revealed that cyclooxygenase-2 (COX-2) is involved in a disturbance in cross-talk between NO and ET-1. COX-2 expression was detected in the endothelial cells of a spastic artery after experimental SAH; however, the pathophysiological significance of COX-2 in relation to CVS remains unclear. The aim of this study was to ...
Source: Translational Stroke Research - April 4, 2016 Category: Neurology Source Type: research

Celebrex Is No Riskier For Heart Than Other Arthritis Drugs, Study Finds
NEW ORLEANS (AP) — A new study gives some reassurance to arthritis sufferers who want pain relief but are worried about side effects. It finds that Celebrex, a drug similar to ones withdrawn 12 years ago for safety reasons, is no riskier for the heart than some other prescription pain pills that are much tougher on the stomach. “We do not want patients to suffer with pain and we need to know what is safe to give them,” said Dr. Steven Nissen, the Cleveland Clinic’s heart chief, who led the study. Fear that Celebrex would be worse than alternatives proved unfounded, and “on almost every endpoint it...
Source: WBZ-TV - Breaking News, Weather and Sports for Boston, Worcester and New Hampshire - November 14, 2016 Category: Consumer Health News Authors: Health – CBS Boston Tags: Health News Arthritis Celebrex Source Type: news

Celebrex study shows less risk to heart health than expected
Researchers spend a decade studying Celebrex, an arthritis drug, to see if it causes heart problems. A similar drug was removed from the market in 2004, as it increased the risk of heart attack and stroke. Dr. Jon LaPook reports.
Source: Health News: CBSNews.com - November 15, 2016 Category: Consumer Health News Source Type: news

Celecoxib ’s Cardiovascular Safety
The selective cyclooxygenase 2 (COX-2) inhibitor celecoxib is no more likely than 2 nonsteroidal anti-inflammatory drugs (NSAIDs) to cause cardiovascular death, nonfatal myocardial infarction, or stroke in patients with coronary disease or other cardiovascular risks.
Source: JAMA - December 27, 2016 Category: Journals (General) Source Type: research

Nonsteroidal anti-inflammatory drugs and cardiovascular safety - translating pharmacological data into clinical readouts.
Authors: Tacconelli S, Bruno A, Grande R, Ballerini P, Patrignani P Abstract INTRODUCTION: The pharmacological management of pain includes the use of nonsteroidal anti-inflammatory drugs(NSAIDs). They comprise traditional(t) NSAIDs and selective cyclooxygenase(COX)-2 inhibitors (named coxibs). The analgesic and anti-inflammatory effects of NSAIDs are dependent on the extent and duration of COX-2 inhibition in the spinal cord and inflammatory sites. However, the simultaneous inhibition of COX-2 in the vasculature translates into a prothrombotic phenotype and promotes hypertension and heart failure. Areas covered. Th...
Source: Expert Opinion on Drug Safety - June 2, 2017 Category: Drugs & Pharmacology Tags: Expert Opin Drug Saf Source Type: research

Celecoxib for rheumatoid arthritis.
CONCLUSIONS: Celecoxib may improve clinical symptoms, alleviate pain and contribute to little or no difference in physical function compared with placebo. Celecoxib was associated with fewer numbers of participant withdrawals. Results for incidence of gastroduodenal ulcers (≥ 3 mm) and short-term serious adverse events were uncertain; however, there were few reported events for either.Celecoxib may slightly improve clinical symptoms compared with tNSAIDs. Results for reduced pain and improved physical function were uncertain. Particpants taking celecoxib had lower incidence of gastroduodenal ulcers (≥ 3 mm) and there w...
Source: Cochrane Database of Systematic Reviews - June 9, 2017 Category: General Medicine Authors: Fidahic M, Jelicic Kadic A, Radic M, Puljak L Tags: Cochrane Database Syst Rev Source Type: research

Randomized trial of switching from prescribed non-selective non-steroidal anti-inflammatory drugs to prescribed celecoxib: the Standard care vs. Celecoxib Outcome Trial (SCOT)
This study excluded an increased risk of the primary endpoint of more than two events per 1000 patient-years associated with switching to prescribed celecoxib.Clinical Trial Registrationhttps://clinicaltrials.gov/show/NCT00447759; Unique identifier: NCT00447759.
Source: European Heart Journal - October 4, 2016 Category: Cardiology Source Type: research

Comparative cardiovascular safety of non ‐steroidal anti‐inflammatory drugs in patients with hypertension: a population‐based cohort study
ConclusionsOur results provide important information about the comparative cardiovascular safety of NSAIDs in patients with hypertension.
Source: British Journal of Clinical Pharmacology - February 22, 2018 Category: Drugs & Pharmacology Authors: Yaa ‐Hui Dong, Chia‐Hsuin Chang, Li‐Chiu Wu, Jing‐Shiang Hwang, Sengwee Toh Tags: DRUG SAFETY Source Type: research

Comparative cardiovascular safety of nonsteroidal anti ‐inflammatory drugs in patients with hypertension: a population‐based cohort study
ConclusionsOur results provide important information about the comparative cardiovascular safety of NSAIDs in patients with hypertension.
Source: British Journal of Clinical Pharmacology - March 13, 2018 Category: Drugs & Pharmacology Authors: Yaa ‐Hui Dong, Chia‐Hsuin Chang, Li‐Chiu Wu, Jing‐Shiang Hwang, Sengwee Toh Tags: DRUG SAFETY Source Type: research